ERJENZ Trademark

Trademark Overview


On Wednesday, April 1, 2015, a trademark application was filed for ERJENZ with the United States Patent and Trademark Office. The USPTO has given the ERJENZ trademark a serial number of 86583902. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Friday, February 3, 2017. This trademark is owned by Actavis, Inc.. The ERJENZ trademark is filed in the Pharmaceutical Products category with the following description:

Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines affecting the sensory organs; Pharmaceuticals and medicines affecting the central nervous system; Pharmaceutica...
erjenz

General Information


Serial Number86583902
Word MarkERJENZ
Filing DateWednesday, April 1, 2015
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateFriday, February 3, 2017
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesOral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines affecting the sensory organs; Pharmaceuticals and medicines affecting the central nervous system; Pharmaceuticals and medicines affecting the urogenital organs; Pharmaceuticals and medicines affecting the circulatory systems; Pharmaceuticals and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceuticals and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression, neuroprotective agent; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, April 10, 2015
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameALLERGAN SALES, LLC
Party Type11 - New Owner Before Publication
Legal Entity Type16 - Limited Liability Company
AddressMADISON, NJ 07940

Party NameActavis, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054

Trademark Events


Event DateEvent Description
Wednesday, January 3, 2018AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Friday, February 3, 2017ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Friday, February 3, 2017ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Wednesday, July 6, 2016NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, July 6, 2016NON-FINAL ACTION E-MAILED
Wednesday, July 6, 2016NON-FINAL ACTION WRITTEN
Friday, June 24, 2016LIE CHECKED SUSP - TO ATTY FOR ACTION
Thursday, June 23, 2016ASSIGNED TO LIE
Tuesday, December 8, 2015NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Tuesday, December 8, 2015LETTER OF SUSPENSION E-MAILED
Tuesday, December 8, 2015SUSPENSION LETTER WRITTEN
Thursday, December 3, 2015TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, December 3, 2015CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, December 3, 2015TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, June 10, 2015NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, June 10, 2015NON-FINAL ACTION E-MAILED
Wednesday, June 10, 2015NON-FINAL ACTION WRITTEN
Thursday, June 4, 2015ASSIGNED TO EXAMINER
Friday, April 10, 2015NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Saturday, April 4, 2015NEW APPLICATION ENTERED IN TRAM